- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
Syntheia
CI Galaxy Bitcoin ETF
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Cannabis Wheaton Gives Update on Facility Development for FV Pharma
Cannabis Wheaton Income gave shareholders an update on the development of the project for its streaming partner FV Pharma.
Cannabis Wheaton Income (TSXV:CBW) provided shareholders with an update on the development of the project for its streaming partner FV Pharma.
As quoted in the press release:
The FV Pharma facility (the “Facility”) is located in Cobourg, Ontario and hosts an existing 620,000 square feet of building space. Since signing a definitive agreement (the “Agreement“) the Company and FV Pharma have been eagerly advancing the design, construction budget and timeline for the development of the Facility.
Pursuant to the Agreement, the Company will develop and finance all aspects of FV Pharma’s Facility in mutually agreed phases of construction and arrange for the build-out, commissioning and operations. The Company will receive a 49.9% stream of all cannabis (or cannabis-derived products including any immature cannabis plants and any cannabis trim) produced at the Facility, under partnership with Cannabis Wheaton, in perpetuity.
The Company has determined that the first phase development of the Facility will be a retrofit of the existing building to construct approximately 100,000 square feet of cultivation and ancillary space (“Phase I”). The Company and FV Pharma are actively working to finalize the funding and timing associated with the development of Phase I which is estimated to cost approximately $35,000,000. It is anticipated that Phase I will be fully completed and licensed within 18 months.
Click here to read the full press release.
Source: globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.